Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918

This study has been terminated.
(PK results demonstrate low and variable plasma concentrations so that achieving therapeutic concentrations is unlikely.)
Information provided by:
AstraZeneca Identifier:
First received: August 8, 2008
Last updated: December 9, 2010
Last verified: December 2010
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD6918 based on the side effects experienced by patients with advanced solid malignancies that receive daily AZD6918 alone. It is possible that AZD6918 will be administered twice daily. Then maximum tolerated doses in combination with either gemcitabine or pemetrexed will also be investigated.

Condition Intervention Phase
Solid Tumors
Advanced Solid Malignancies
Drug: AZD6918
Drug: gemcitabine
Drug: pemetrexed
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6918 Administered Daily as a Single Agent and in Combination Treatment in Adult Patients With Refractory Solid Malignancies

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Assessment of adverse events (based on CTCAE version 3.0), laboratory values, vital sign measurements, Karnofsky performance status [ Time Frame: Weekly for first two treatment cycles, then every 2-4 weeks ]

Secondary Outcome Measures:
  • Pharmacokinetic effect of AZD6918 when administered alone and in combination with chemotherapy [ Time Frame: According to protocol specified schedule, the number of PK samples collected during Cycle 1 (up to 28 days) based on treatment with AZD6918 alone or in combination with chemotherapy ]

Estimated Enrollment: 75
Study Start Date: August 2008
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: gemcitabine
gemcitabine administered in combination with AZD6918
Drug: gemcitabine
intravenous, doses are on an intermittent schedule
Other Name: Gemzar
Experimental: pemetrexed
pemetrexed administered in combination with AZD6918
Drug: pemetrexed
intravenous, dose administered every 21-days
Other Name: Alimta
Experimental: AZD6918
AZD6918 administered alone
Drug: AZD6918
liquid suspension, daily, oral dose


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Advanced solid tumors for which standard treatment does not exist or is no longer effective.
  • For chemotherapy combination treatment, must be suitable for treatment with either gemcitabine or pemetrexed.
  • Relatively good overall health other than cancer.

Exclusion Criteria:

  • Poor bone marrow function (not producing enough blood cells).
  • Poor liver or kidney function.
  • Serious heart conditions
  • History of uncontrolled epilepsy, Parkinson's disease, Alzheimer's disease, brain tumor or any uncontrolled psychiatric or nervous system condition
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00733031

United States, Colorado
Research Site
Aurora, Colorado, United States
United States, Tennessee
Research Site
Nashville, Tennessee, United States
Sponsors and Collaborators
Study Director: Judith Ochs, MD AstraZeneca
Principal Investigator: Jeffrey Infante, MD SCRI Development Innovations, LLC
Principal Investigator: Lia Gore, MD University of Colorado, Denver
  More Information

Responsible Party: Judith Ochs, M.D. Medical Science Director, AstraZeneca Pharmaceuticals, LP Identifier: NCT00733031     History of Changes
Other Study ID Numbers: D2785C00002
Study First Received: August 8, 2008
Last Updated: December 9, 2010

Keywords provided by AstraZeneca:
Phase I,
solid tumors,
advanced solid malignancies,
dose escalation,
combination treatment,
TRK inhibitor

Additional relevant MeSH terms:
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors processed this record on April 21, 2017